Kent S. Bernard retired as Vice President & Assistant General Counsel of Pfizer Inc. at the end of 2007. Kent started at Pfizer as an antitrust litigation attorney in 1980. He then represented Pfizer’s bulk chemical operations, later becoming the senior lawyer for Pfizer’s worldwide animal health business, all the while continuing to work on antitrust and competition law matters.
In the course of his M&A work Kent helped acquire Schneider Medintag, a maker of sophisticated interventional cardiology devices that grew to become the most profitable company within the Pfizer Medical Devices group. Kent then served as General Counsel to that business, before actively assisting in negotiating its sale out of Pfizer, after the decision to divest those businesses, some years later. At the time of his retirement Kent was the head of the Pfizer Antitrust Group, advising on all antitrust functions and antitrust litigation, as well as competition law matters worldwide. He also was the Deputy Managing Partner of the Pfizer Legal Division.
In his antitrust and competition law capacity, Kent worked in planning, structuring, clearing and implementing business arrangements on a worldwide basis. He also advised on a competition law investigations, as well as antitrust litigation with both government agencies and private parties.
Kent is a magna cum Laude 1975 graduate of the University of Pennsylvania Law School where he was an Article Editor of the Law Review. He began his career in Philadelphia as an attorney in private practice. He then went in-house, and in the 1980, joined the Legal Division at Pfizer.